+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Transplant market set to grow to $45bn by 2024” says new Visiongain report

18 December 2018
Pharma

Visiongain has launched a new pharma report Global Transplant Market Report : Tissue Products, Immunosuppressive Drugs, Preservation Solutions, Tissue Transplant, Organ Transplant, Heart Valve, Vascular Grafts, Bone Grafts, Cornea, Skin Grafts, Bone Marrow, Other Tissues, Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Pancreas Transplant, Other Transplant, Hospitals, Transplant Centres, Other End-Users.

The worldwide rise in the demand for tissue or organs for transplant can be attributed to upsurge in the incidence of acute or chronic diseases. For instance, high blood pressure and diabetes are the foremost causes of end-stage kidney conditions, where kidney transplantation or dialysis is the solitary treatment possibilities to save a patient’s life. As stated by the National Kidney Foundation, there were approximately 122,737 patients in the U.S., who are waiting to receive organs for transplantation in 2014. Thus, there is growing demand for high-end tissue products for the treatment of organ damage or failure, and leukaemia treatment.

The lead analyst of the report commented "Rising number of transplant surgeries, escalating prevalence of chronic diseases, and developing healthcare infrastructure in emerging economies such as China, India, South Africa, Brazil, Mexico, and Indonesia are factors that will drive the demand for transplant products. However, factors such as lack of skilled professionals and high cost of organ transplant surgeries are expected to limit the market growth."

Leading companies featured in the report include AbbVie, Inc., Arthrex, Inc., Medtronic, Novartis AG, Stryker, Teva Pharmaceuticals, Veloxis Pharmaceuticals, Zimmer Biomet

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever